NANOLEK is the first in Russia to produce inactivated polio vaccine.

On 11th of November, there has been a grand opening of an innovative vaccines and biotechnological production of NANOLEK located in Kirov. The new production is based on the most modern technologies, some of which are pioneer representatives in Russia, and fits high-set international quality standards, which is demonstrated by numerous partnerships with large multinational companies (Sanofi Pasteur, Merck, Celltrion, Egis, Aspen, TEVA etc.) which results in a number of socially important products brought into Russian market.

 

Since late 2014, the factory has been producing medications in solid dosage forms: products of its own development as well as those within the framework of contract manufacturing. In a biotechnological site of NANOLEK products in vial and parenteral dosage forms will now be manufactured with volumes predicted to reach up to 42 million pre-filled syringes and 35 million vials per year. The area of land around the plant pledges further expansion and an increase in output quantities.

 

From the foundation day the company has been actively developing a set of vaccines aiming at completing and further growth of the National Vaccination Calendar. The first vaccine to be produced by NANOLEK will be POLIMILEX – an inactivated vaccine for polio prevention, with state registration expected to be completed in the nearest time. The vaccine will become the first inactivated polio vaccine to be manufactured in Russia. In partnership with Bilthoven Biologicals (Netherlands) NANOLEK has been conducting a transferal of the vaccine’s production technology to the biomedical plant from 2012, with vaccine supply for public health services in Russia planned to begin in 2017.

 

The government is currently passing on a policy targeting the extension of use of the inactivated polio vaccine within the confines of National Food Industry Commission, which totally supports the strategy of the World Health Organization, which aims at a global annihilation of polio and allows to eliminate the chance of getting infected through a vaccine-associated polio completely. As many epidemiologists claim, there are two types of polio vaccines - an inactivated poliovirus vaccine (IPV) and an oral poliovirus vaccine (OPV). Contact with people, vaccinated with the latter may pass on the infection to those, who haven’t undergone vaccination yet. This is the origin of the so-called vaccine-associated polio. To avoid those cases, in 1990s the first two vaccinations were IPVs. This significantly dropped the probability of getting a “handmade” infection and moreover it allowed children who were intolerant to OPV to be vaccinated.

 

Considering the global deficit of demand for the inactivated polio vaccine, in future, as the production continues to expand, there is a scope for international growth, including UNICEF.

 

Vladimir Khristenko, president of NANOLEK: “In the nearest future NANOLEK is planning to become one of the leading vaccine producers in Russian Federation, accumulating the investments and the existing experience of the world market, as well as the experience of our foreign partners. At the moment, we have completed an investment stage of development and we are now moving on to implementation of manufacturing projects regarding the production of both our own and our partners’ medicaments. A lot has been done, but there will be even more, taking into account the output volumes of our plant with possibilities to increase the power and make the company evolve in areas of research and innovation”.

 

“In the first place the plant is aimed at implementation of import substitution policy,” – said Igor Vasiliev, Executive Governor Of Kirov Region, – “It’s operation not only decreases the price of medicaments, provides safety in vaccine and other drugs production but also ensures introduction of new, innovative, domestic medicaments into Russian market.

 

“Production of innovative drugs in Russia at the 21st century level is one of RUSNANO’s priorities.  In today’s market when the availability of imported drugs has decreased significantly, technology transfer and domestic localization of manufacture in Russia becomes not only economically expedient but for some – a question of life and death. NANOLEK, one of institutions that were built with our help, is a massive plant even at a global level. Today, looking at manufacturing factories and laboratories it is hard to believe that only five years ago there was nothing there except for a plain field. Now it is one of the biggest manufacturing platforms where five multinational pharmaceutical companies are beginning to produce their products. An institution that was able to double the revenues within three quarters of 2016 is an institution with a massive growth potential. In fact, it is now sad that in several years we will have to sell our share that is virtually a third of the business. Nevertheless, pharmaceutical industry will always be one of our main focuses” – said Anatoly Chubais, Chairman of Board, RUSNANO.

 

Nikolai Podguzov, Deputy Minister of Economic Development of the Russian Federation: “I am very pleased that the Economic Development Ministry is involved in implementation of this successful project. It is a very interesting example of a private state partnership the goals of which are entrepreneurship and private businesses. We have supported the project in 2015. It was probably one of the most difficult periods in terms of financial resources, and our policy to support projects based on project financing was, in my opinion, very successful. We are delighted that the day has come and the project has started functioning in time. We hope that in future we will support more projects of this kind, including those in Kirov region, including those aimed at development of non-primary potential of our country, offering effective and successful tools.